You are here

  • Home
  • Archive
  • Volume 79, Issue 10
  • Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

Article metrics

Article menu

Download PDFPDF

XML
Autoinflammatory disorders
Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial

 

Online download statistics by month:

Online download statistics by month: June 2020 to March 2024

AbstractFullPdf
Jun 2020506483129
Jul 2020374359104
Aug 202017616653
Sep 2020413402124
Oct 2020382373102
Nov 202019218367
Dec 202017316154
Jan 202113613147
Feb 202111210832
Mar 202114112954
Apr 202116115351
May 202118017545
Jun 20211039754
Jul 2021868341
Aug 2021848353
Sep 202111010721
Oct 202111911544
Nov 202111410971
Dec 2021858430
Jan 2022777731
Feb 2022757935
Mar 2022969636
Apr 2022777929
May 202211211457
Jun 2022999931
Jul 2022787931
Aug 2022818945
Sep 2022748127
Oct 202210010235
Nov 202210310443
Dec 2022615731
Jan 2023777435
Feb 2023939031
Mar 20231039230
Apr 2023938832
May 2023787435
Jun 2023777933
Jul 2023787735
Aug 202311711627
Sep 2023959025
Oct 202313012530
Nov 202314714640
Dec 2023898718
Jan 20245045101
Feb 2024745829
Mar 202410710095
Total608858982203